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Abstract  
Background: Anxiety and depression are common, debilitating and costly. These disorders are 
influenced by multiple risk factors, from genes to psychological vulnerabilities and environmental 
stressors, but research is hampered by a lack of sufficiently large comprehensive studies. We are 
recruiting 40,000 individuals with lifetime depression or anxiety and broad assessment of risks to 
facilitate future research. 
Methods: The Genetic Links to Anxiety and Depression (GLAD) Study (www.gladstudy.org.uk) recruits 
individuals with depression or anxiety into the NIHR Mental Health BioResource. Participants invited to 
join the study (via media campaigns) provide demographic, environmental and genetic data, and 
consent for medical record linkage and recontact. 
Results: Online recruitment was effective; 42,531 participants consented and 27,776 completed the 
questionnaire by end of July 2019. Participants’ questionnaire data identified very high rates of 
recurrent depression, severe anxiety, and comorbidity. Participants reported high rates of treatment 
receipt. The age profile of the sample is biased toward young adults, with higher recruitment of females 
and the more educated, especially at younger ages.   
Discussion: This paper describes the study methodology and descriptive data for GLAD, which 
represents a large, recontactable resource that will enable future research into risks, outcomes, and 
treatment for anxiety and depression. 
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Highlights 
● Online recruitment of 40,000 individuals with lifetime depression or anxiety 
● Detailed online phenotyping combined with genetic and clinical data 
● The study sample is severe, highly comorbid, with chronic psychopathology 
● The study protocol enables recall of participants for future research and trials 
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Introduction 
Anxiety and depression are the most common psychiatric disorders worldwide, with a lifetime 
prevalence of at least 30% (Kessler et al. 2005; Bandelow and Michaelis 2015). Both are highly comorbid 
with each other and with other psychiatric disorders (Mineka, Watson, and Clark 1998), and account for 
10% of all years lived with disability (World Health Organisation 2017). The World Health Organisation 
now considers depression to be the number one disorder by burden of disease (World Health 
Organisation 2017). Many risk factors for depression and anxiety are shared, including psychological 
(e.g. cognitive biases (Naragon-Gainey 2010; Michl et al. 2013)), environmental (e.g. stressful life events 
(Michl et al. 2013)), and genetic influences (which are ~60-100% shared (Waszczuk et al. 2014; Purves et 
al. 2017)). These findings on aetiology have been accompanied by an increasing evidence base of 
effective treatments, especially psychological (talking) therapies (Deacon and Abramowitz 2004; 
Hofmann and Smits 2008; Dobson 1989). Nevertheless, despite advancements in psychological therapies 
as well as medication, clinicians are unable to predict which treatment will work for whom. This means 
that the choice of first and subsequent treatments currently progresses by trial and error at the cost of 
prolonged disability, reduced hope of success/engagement, and increased risk of adverse events (Perlis 
2016; Rush et al. 2006). 
 
Decades of work estimate twin study heritability of both anxiety and depression at ~30-40% (Sullivan, 
Neale, and Kendler 2000), rising to ~60-70% for the recurrent forms of these disorders across several 
years (K. S. Kendler et al. 1993). Recent UK Biobank analyses confirm that common genetic variants 
(single nucleotide polymorphisms, or “SNPs”) account for a smaller but still significant ~15-30% of 
variation (“SNP-heritability”) in lifetime anxiety (Purves et al. 2017). Depression has a SNP-heritability of 
~12-14% and shows substantial genetic overlap with anxiety (Purves et al. 2017). Recent genome-wide 
association studies (GWAS) have identified 102 genetic variants for depression and closely related 
phenotypes (Howard et al. 2019) and 5 genetic variants for anxiety (Purves et al. 2017), indicating that 
we are now entering the era where it will be possible to finally discover new biology for both disorders. 
In addition, these genetic advances suggest that it may be time to include genetic risk factors in research 
aimed at developing new treatments or predicting which therapies will work best for each patient (Keers 
et al. 2016; Lewis and Vassos 2017; Gaspar et al. 2018; Breen et al. 2016).  
 
Both GWAS and sequencing studies have shown that there are few, if any, individual genetic variants 
with a large effect size. Instead, the overall heritability is made of the effect of many (probably 
thousands) genetic variants that individually have small effects. This type of genetic architecture is now 
commonly referred to as being polygenic. As such, almost all disorders affecting >0.5% of the population 
that show moderate to high heritability are now referred to as polygenic disorders. The use of genome-
wide methodology has also confirmed that psychiatric genetics has moved beyond its replication crisis, 
as its results have proven much more replicable than those of candidate gene studies (Border et al. 
2019). 
 
Despite the broad range of established risk factors (Craske et al. 2017; Fliege et al. 2009; Burcusa and 
Iacono 2007), it is unclear how different types of influences combine to increase risk and influence 
treatment response. In particular, clinical/psychological (e.g. comorbidities), demographic (e.g. age), 
environmental (e.g. life events), and genetic influences have been studied largely independently, despite 
their evident interplay (Kendler, Gardner, and Prescott 2002). As such, more multidisciplinary research is 
needed. However, efforts to better understand the aetiology of these disorders require large sample 
sizes and detailed information on symptom presentation. Many studies exist worldwide with either the 
scale of participants or the thorough phenotyping needed, but few have both. In response to this, the 
Genetic Links to Anxiety and Depression (GLAD) Study was developed to recruit >40,000 individuals into 
the newly established National Institute for Health Research (NIHR) Mental Health BioResource. Our 
sample size was based on the available funding and our aim to be one of the largest single studies (as 
opposed to previous meta-analyses) of individuals with a lifetime experience of clinical depression and 
anxiety, providing sufficient power for discovery analyses and for recall studies. 
 
The NIHR Mental Health BioResource is an integral part of the overall NIHR BioResource for 
Translational Research (https://bioresource.nihr.ac.uk/), which has previously recruited approximately 
100,000 individuals. However, a large majority of these volunteers were either healthy controls or have 
a physical health condition with no reported mental health disorder. This gap led to the creation of the 
NIHR Mental Health Bioresource. GLAD is its first project and has the specific goal of recruiting a large 
number of participants with anxiety and depression to facilitate future recall and secondary data 
analysis studies. Recall studies would involve recontacting participants to take part in further research, 
such as clinical trials aimed at developing better therapies and interventions for anxiety and depression. 
The GLAD Study will also directly explore both genetic and environmental risk factors for depression and 
anxiety disorders, including the potential of polygenic risk scores (Purcell et al. 2009) created from 
analyses of related phenotypes to predict response to treatment and prognosis. GLAD aims to facilitate 
studies which need to combine genetic, phenotypic, and environmental exposure data by creating a 
large, homogeneously phenotyped cohort of individuals with depression or anxiety with all these types 
of data. 
 
Methods 
Pre-Launch Preparation 
A focused and intense social media campaign was utilised to inform the public about the GLAD Study. 
We hoped that individuals with anxiety and depression would be encouraged to join given the online 
methodology, allowing them to respond to the questionnaires in a convenient time and location. The 
timeline leading up to the media launch is outlined in Figure 1. Experts in the field, patients, and 
individuals with lived experience of depression or anxiety were consulted at each stage of study 
development. The study team also consulted regularly with collaborators from the Australian Genetics 
of Depression Study who provided guidance and advice based on their experience of successfully 
implementing a similar study design in Australia (Byrne et al. 2019). 
Figure 1. Steps to prepare for launch of the GLAD Study  
 
 
 
 
 
 
 
 
 
 
 
  
 
Website Development, Design, and User Testing 
The website was developed in collaboration with a local company (Mindwave Ventures) in various 
stages. During the early stages of development and the design phase, we conducted user testing on the 
website by contacting individuals with lived experience through various routes. The first user testers 
were patient volunteers within the Improving Access to Psychological Therapies (IAPT) service at South 
London and Maudsley (SLaM) National Health Service (NHS) Foundation Trust. The second group of 
volunteers were members of the King’s College London Service User Research Enterprise (SURE) and the 
Feasibility and Acceptability Support Team for Researchers (FAST-R). Third were volunteer individuals 
with lived experience who were actively involved with the charity Mind. Finally, staff from the charities 
Mind, MQ Mental Health, and the Mental Health Foundation gave feedback. All individuals provided 
input on the website content and usability, appearance, and study information and all volunteers (but 
not charity staff) were compensated £10 for their time. All feedback was reviewed by the study team 
and the lead investigators and incorporated into the final version of the website. 
 
GLAD Study Spokespeople 
A wide range of charities, professional bodies, companies, influencers (defined as individuals with a 
large number of followers on social media), and individuals with lived experience were identified based 
on previous advocacy, involvement, or openness of mental health and treatment. These individuals and 
organisations were approached by the public relations (PR) company (Four Health Communications), the 
study team, and/or the co-investigators to introduce the study and invite them to collaborate. 
 
We received support from many UK charities including Mind, MQ, Mental Health Foundation, Anxiety 
UK, OCD Action, Bipolar UK, HERO, No Panic, the Charlie Waller Memorial Trust, BDD Foundation, 
Maternal OCD, Rethink Mental Illness, SANE, MHFA England, Universities UK, and UK Youth. We also 
received significant support from two UK professional bodies for psychologists and psychiatrists, the 
British Psychological Society and the Royal College of Psychiatrists.  Finally, three organisations (Royal 
Mail, Priory Group, and Barnardo’s) agreed to circulate study information internally to their employees, 
and Priory Group additionally shared study information on social media. 
 
Many of the charities, professional bodies, and influencers provided a quote about the GLAD Study to be 
shared with news outlets and on social media. Other forms of support from charities or professional 
bodies included circulating study information in member newsletters or magazines, publishing study 
information on their websites, and sharing the study on social media (http://wke.lt/w/s/Ymfhz). 
Influencers helped to promote the study on their social media channels or blogs. Individuals with lived 
experience allowed the GLAD Study team to share their stories on social media and news outlets. Of 
utmost importance, these individuals were available for interviews with broadcast and newspaper 
agencies and gave a personal voice to the campaign. Spokespeople who became actively involved in the 
publicity and circulation of the GLAD Study in the media and/or online were vital to the success of the 
campaign. 
 
Standard Operating Procedures and Templates 
We created a variety of standard operating procedures (SOPs) and response templates to prepare for 
the logistical and administrative aspects of study launch and management. These included SOPs for 
saliva sample kit preparation and posting, website management, data protection, and participant 
contact. We established guides and SOPs for both email and social media responses to participant 
questions, concerns, and expressions of distress. These guidelines were reviewed by clinicians and by 
the Mental Health Foundation to ensure responses were appropriate, straightforward, and clear. 
 
Social Media Content and Visuals 
Social media content and visuals were designed with the aid of the PR company (which had experience 
of working on NHS projects), an independent videographer, and an animation company. These included 
a range of infographics and short videos, each designed to be informative and provide basic details for 
the public about the aims of GLAD and how to join the project. The campaign was targeted to a younger 
demographic (age 16 - 30) to enable more prolonged collection of longitudinal data and reflect the 
young age of onset of depression and anxiety disorders (Bandelow and Michaelis 2015; Christie et al. 
1988; Kessler et al. 2005). 
 
The infographics (Figure 2) emphasised the simplicity and ease of taking part. The consent animation 
(https://youtu.be.com/SAE0yVNvWaA) outlined key elements of the consent process to provide a 
simple and clear way to learn about the study, consistent with guidance from the Health Research 
Authority regarding multimedia use as a patient-friendly method of delivering vital consent information 
(Health Research Authority 2017). The consent animation was also included with the website version of 
the information sheet. The second video was a short film (https://youtu.be/wzgvS8gU2Ss) which 
outlined the study sign-up steps in a real-life, relatable way. Finally, the animation 
(https://youtu.be.com/HUI5eFXevvk) was an engaging ‘call to action’ to join the community of 
volunteers participating in the GLAD Study. 
 
 
 
 
 
 
 
 
Figure 2. GLAD Study infographic shared on Twitter 
 Example of the infographic shared on Twitter to promote the GLAD study and explain the key steps involved in signing up 
 
We created a six-week social media schedule for planned posts across Facebook, Instagram, and Twitter 
platforms which included both organic and promoted content. Most of the posts were accompanied by 
a video, infographic, or other imagery developed by the study team. 
 
Outreach to News Outlets 
The PR company circulated the press release and study information to news and broadcast agencies 
across England, and later across the rest of the UK. Interested parties organised interviews with the 
study investigators and/or influencers, charity or professional body representatives, and individuals with 
lived experience. The press releases and broadcasts were embargoed until the launch date to prevent 
pre-emptive publicity and provide uniform, widespread coverage across different media.  
 
Recruitment 
Media Campaign: Study launch 
The PR company helped us to organise a widespread national media campaign which included 
traditional media (TV, radio, newspaper) and social media (Twitter, Facebook, Instagram) outreach 
during the study launch. Examples from the campaign can be viewed at this link: 
http://wke.lt/w/s/Ymfhz. In the first 24 hours, 8,004 participants had registered to the website, 
demonstrating the effectiveness of this strategy. The prepared social media schedule helped to maintain 
our recruitment numbers over the six-week period. Between 300-1,500 participants signed up to the 
study daily, with numbers fluctuating based on campaign expenditure and social media support from 
influencers and organisations.   
 
Five months after the initial launch, the GLAD Study opened in Northern Ireland, Scotland, and Wales, in 
collaboration with researchers at Ulster University1, the University of Edinburgh, and Cardiff University. 
The press offices of the respective universities organised media outreach to local and national news 
outlets, and the PR company assisted in targeted social media advertisements for the various countries. 
 
Clinical Recruitment 
In the 10 months following the launch, many NHS organisations in England contacted us interested in 
supporting the GLAD Study. As of July 2019, these included 12 Clinical Research Networks (CRN), 7 
family doctor/general practitioner (GP) practices, 96 Trusts, 1 Clinical Commissioning Group (CCG), and 2 
GP Federations. Sites were classified in 2 different categories with varying levels of involvement: 1) 
advertising sites which displayed study posters and leaflets in clinics and waiting areas, and 2) recruiting 
sites which conducted mail-outs, approached patients in the clinic or over the phone, and assisted 
patients through the study sign-up process. 
 
Sign-up Process 
The sign-up process for enrolment in GLAD is given in Figure 3. Personal information and phenotypic 
data are collected entirely online through the GLAD Study website (www.gladstudy.org.uk). Participants 
register on the website with their name, email address, phone number, date of birth, sex, and gender. 
They are then able to read the information sheet and provide consent. As part of the consenting process 
participants agree to long-term storage of their sample, requests to complete follow-up questionnaires, 
anonymised data sharing, recontact for future research studies based on their phenotype/genotype 
information, and access to their full medical and health related records. Following consent, participants 
complete the sign-up questionnaire to assess their eligibility. Eligibility criteria are restricted to 
participants that meet DSM-5 criteria for MDD or any anxiety disorder, based on responses to screening 
measures in our online sign-up questionnaire. More information about the measures in the sign-up 
questionnaire are included below. Eligible participants are then sent an Isohelix saliva DNA sample kit. 
Saliva samples are sent via Freepost to the NIHR National Biosample Centre in Milton Keynes for 
processing and storage. Once participants have returned their saliva sample, they become full members 
of the GLAD Study (and of the NIHR BioResource) and are eligible to take part in future studies.  
 
Email reminders are sent to participants who do not complete their sign-up steps. Up to four automated 
reminder emails are sent through the website up to six months post starting sign-up. Once online sign-
up steps are completed, a maximum of four reminder emails are sent to participants regarding the saliva 
samples up to six months from the date the kit was sent. We conduct additional phone call or text 
message reminders to participants who have not returned their saliva kits within three months of 
signing-up.   
 
Clinical data will be linked to genotype and phenotype data to provide additional information about 
participants’ medical history, diagnoses, and treatments relevant to current and future research 
projects. Eligibility for collaborating studies can then be assessed utilising all phenotypic, genetic, and 
clinical data. Members may then be contacted up to four times per year to take part in future studies, 
either through the website or by the GLAD Study or NIHR BioResource teams, with access granted via 
established NIHR BioResource access protocols (see below for further detail). As part of the community 
of members, participants will also have access to useful information and links on the “Useful Links” page 
                                                          
1
 Professor Chérie Armour, the Principal Investigator (PI) in Northern Ireland (NI) moved institution during the course of the 
study from Ulster University to Queens University Belfast, remaining as the NI PI. 
of the study website. Members will also be invited to take part in follow-up questionnaires to provide 
longitudinal data on their symptoms. 
 
Figure 3. Stages of participant sign-up and involvement in the GLAD Study 
 
 
Measures 
Sign-up Questionnaire 
The sign-up questionnaire was designed to assess core demographic and personal information as well as 
detailed psychological and behavioural phenotyping relevant to anxiety and depression (for full measure 
names see Table 1). We included lifetime measures of major depressive disorder (MDD), atypical 
depression, and generalised anxiety disorder (GAD, adapted from CIDI-SF (Patten et al. 2000) and ICD-11 
checklists (Kogan et al. 2016), supplemented with items enabling lifetime assessment of DSM-5 specific 
phobia, social phobia, panic disorder and agoraphobia. These items were adapted from the Australian 
Genetics of Depression Study questionnaire (Byrne et al. 2019).  
 
We also assessed current depressive symptoms (PHQ-9 (Kroenke, Spitzer, and Williams 2001)), and 
those with a score of five or above on the PHQ 9 (indicating a current episode of depression) were asked 
additional questions related to current treatment-resistant depression (MSM-SR (Fekadu, Donocik, and 
Cleare 2018)). Other measures of current psychopathology included possible mania/hypomania (MDQ 
(Hirschfeld 2002)), current general anxiety symptoms (GAD-7 (Spitzer et al. 2006)), post-traumatic stress 
disorder symptoms (PCL-6 (Lang et al. 2012)), alcohol use (AUDIT-C (Saunders et al. 1993)), psychotic 
symptoms (adapted CIDI (McGrath et al. 2015)), personality disorder symptoms (SAS-PD (Olajide et al. 
2018)), and work and social adjustment (WSAS (Mundt et al. 2002)). Additional measures were included 
to assess subjective well-being (WHOQOL Group 1994), recent adverse life events, five childhood 
trauma items (Glaesmer et al. 2013) representing the five subscales of the full Childhood Trauma 
Questionnaire (Pennebaker and Susman 2013), domestic violence (Davis et al. 2018), and catastrophic 
trauma (Davis et al. 2018). 
 
To facilitate future meta-analyses with other cohorts, measures were selected when possible to align 
with the UK Biobank Mental Health Questionnaire (MHQ) (Davis et al. 2018). Participants were also 
asked to report if they have taken part in the UK Biobank. Some aspects of the UK Biobank MHQ were 
not selected for the sign-up questionnaire in order to make space for additional measures more relevant 
here. Furthermore, detailed questions on self-harm and suicide were not asked during sign-up due to 
concerns from the study team and the SLaM Research and Development (R&D) department of 
insufficient clinical support in the case of reported adverse events, although the single suicidal ideation 
item in the PHQ-9 was retained as this measure is validated and widely used.  
 
Table 1. GLAD Study sign-up questionnaire measures 
Assessment/Topic Purpose Source 
Lifetime depression 
Lifetime assessment of major 
depressive disorder 
Adapted Composite International Diagnostic 
Interview – Short Form (CIDI-SF) 
 
Lifetime atypical depression 
Lifetime assessment of atypical 
depression Adapted DSM-5/ICD-11 checklists 
 
Lifetime anxiety 
Lifetime assessment of generalised 
anxiety disorder 
Adapted Composite International Diagnostic 
Interview – Short Form (CIDI-SF) 
Lifetime specific phobia Lifetime assessment of specific phobia Adapted DSM-5/ICD-11 checklists 
Lifetime social phobia Lifetime assessment of social phobia Adapted DSM-5/ICD-11 checklists 
Lifetime panic disorder Lifetime assessment of panic disorder Adapted DSM-5/ICD-11 checklists 
Lifetime agoraphobia Lifetime assessment of agoraphobia Adapted DSM-5/ICD-11 checklists 
Current depressive symptoms 
Assess severity and presence/absence 
of current depression. Patient Health Questionnaire 9-items (PHQ-9)  
Treatment-resistant 
depression 
Assess treatments during most recent 
or current depressive episode to 
screen for treatment-resistant 
Maudsley Staging Model of Treatment 
Resistance, Modified Self-Report (MSM-SR)  
Possible mania/hypomania 
Screen participants for possible 
episodes of hypomania or mania The Mood Disorder Questionnaire (MDQ)  
Current general anxiety 
symptoms 
Assess the severity and 
presence/absence of current anxiety 
Generalised Anxiety Disorder 7-item scale 
(GAD-7)  
Current post-traumatic stress 
disorder symptoms 
Screen for presence and severity of 
PTSD symptoms. 
Post-traumatic stress disorder checklist, 
civilian version 6-items (PCL-6)  
Alcohol use 
Screen for alcohol dependence in the 
past year 
Alcohol Use Disorders Identification Test 
(AUDIT)  
Psychotic symptoms Assess lifetime psychotic experiences Adapted CIDI 
Personality disorders 
Assess the severity of personality 
disorders. 
Standardized Assessment of Severity of 
Personality Disorder 9-items (SASPD)  
Work and social adjustment 
Assess functional impairment due to 
psychopathology Work and Social Adjustment Scale (WSAS)  
Subjective wellbeing 
Assesses subjective well-being, 
specifically positive emotion and 
meaning 
Two hedonic ('positive emotion') questions 
and a eudaimonic ('meaning') question from 
WHO-Quality of Life (WHOQOL)  
Adversities in childhood 
Identify presence/absence of 
childhood abuse and neglect 
Childhood Trauma Screener short version 
(CTS-5)  
Adult domestic abuse and 
catastrophic trauma 
Identify victims of adult domestic 
abuse. 
A 5-item domestic abuse screen developed 
for the UK Biobank Mental Health 
Questionnaire, adapted from the national 
crime survey and CTS-5, and 5 items on 
catastrophic trauma 
 
Optional Questionnaires 
Once participants completed the sign-up questionnaire, they were invited to take part in additional, 
optional questionnaires (SM 1). Optional questionnaires to assess a wider number of psychiatric 
phenotypes and symptoms included measures of fear (Fear Survey Schedule (Wolpe and Lang 1964)), 
drug use (DUDIT (Berman et al. 2003)), obsessive-compulsive disorder (OCI-R (Foa et al. 2002)), post-
traumatic stress disorder (PCL-5 (Weathers et al. 2013)), trauma (Kopenen, personal communication), 
postnatal depression (EPDS (Cox, Holden, and Sagovsky 1987)), body dysmorphic disorder (DCQ 
(Mancuso, Knoesen, and Castle 2010)), eating disorders (Thornton et al. 2018; Herman et al. 2016; 
Allison, Stunkard, and Thier 2004; Hildebrandt, Langenbucher, and Schlundt 2004), and vomit phobia 
(SPOVI (Veale et al. 2013)). 
 
Other optional projects relate to lifestyle and personal history, asking detailed questions on participants’ 
experience of healthcare, life events (Weathers et al. 2013), work and sleep, general health and lifestyle, 
gambling, and headaches and migraines (Byrne et al. 2019). Optional questionnaires were made 
available to all participants, except those on vomit phobia and postnatal depression which were only 
offered to participants based on responses to screening questions in the sign-up questionnaire. 
Additional follow-up questionnaires will be sent to participants annually to provide longitudinal data on 
symptoms and outcomes. 
 
Genotyping 
All GLAD samples will be genotyped as part of core NIHR BioResource funding. For genotyping we are 
using the UK Biobank v2 Axiom array, consisting of >850,000 genetic variants (Bycroft et al. 2018), 
designed to give optimal information about other correlated genetic variants. This careful design means 
that imputation of the data with large whole genome sequencing reference datasets will yield >10 
million common genetic variants per individual. We use Affymetrix software and the UK Biobank 
pipeline software to assign genotypes and perform standard quality control measures in PLINK (Chang et 
al. 2015) or equivalent software packages and R (Team 2015). Analyses will be conducted in PLINK in the 
first instance. 
 
Ethical Approval 
The GLAD Study was approved by the London - Fulham Research Ethics Committee on 21st August 2018 
(REC reference: 18/LO/1218) following a full review by the committee. The NIHR BioResource has been 
approved as a Research Tissue Bank by the East of England - Cambridge Central Committee (REC 
reference: 17/EE/0025). Prior to submission for ethical approval, this research was reviewed by a team 
with experience of mental health problems and their carers who have been specially trained to advise 
on research proposals and documentation through the Feasibility and Acceptability Support Team for 
Researchers (FAST-R): a free, confidential service in England provided by the NIHR Maudsley Biomedical 
Research Centre via King’s College London and South London and Maudsley NHS Foundation Trust. 
 
 
 
 
 
Analysis 
Genetics and combined predictors of anxiety and depression 
The GLAD data can be used alongside UK Biobank for meta-analyses, with UK Biobank participants 
and/or other NIHR Bioresource participants as healthy controls, to maximise statistical power. One of 
our primary genomic aims is to utilise polygenic scores created from very large genome-wide analyses of 
related traits (e.g. anxiety) as potential predictors of depression, anxiety, and treatment response in our 
sample. There are a number of well-powered polygenic scores now available in the field not only for 
psychiatric traits but also intelligence and its proxies (Selzam et al. 2017) and other relevant predictors. 
We aim to combine these polygenic scores with significant clinical predictors to produce a combined 
clinical/genetic risk index.  
 
We envision the GLAD sample to also be incorporated either in large genome-wide association studies, 
contributing to meta-analyses, or in clinical trials, for example researching genetic, epidemiological or 
social risk factors of anxiety and depression. 
 
Future Research and Collaborations 
Researchers wishing to access GLAD Study participants or data are invited to submit a data and sample 
access request to the NIHR BioResource to request a collaboration, following the procedures outlined in 
the access request protocol (SM 2). Applications will be reviewed by the NIHR Steering Committee to 
assess the study aims and to check ethical approvals and protocols. Collaborations can range from 
sharing of anonymised data or samples to recontact of participants for additional studies, including 
experimental medicine studies and clinical trials. Eligibility for future research can be targeted to specific 
genotypes and/or phenotypes of interest. 
 
Results 
Sample Descriptors 
Recruitment of the GLAD Study is ongoing. All results that follow are from participants recruited before 
25 July 2019. As of this date, 42,531 participants had consented to the GLAD Study, with approximately 
35% drop-off rate at each stage of the sign-up process. This resulted in 27,991 (65.8%) having completed 
the questionnaire, with 27,776 (99.2%) screened as eligible and sent a saliva kit. Of those participants 
which were sent a kit, 18,663 (67.2%) have returned a saliva sample thus far. 
 
In the current sample, the mean age is 38.1 with most participants being female, white, and in paid 
employment or self-employed (Table 2). The GLAD sample is younger and more female (Figure 4) and 
has a higher proportion of individuals with a university degree (Figure 5) than the general UK 
population. For example, 13.1% of our sample is female aged 25-29 compared to only 4.2% of the UK 
population. This difference is seen across all age groups under 60. Similarly, in the age-range 25-34 
years, 68.9% of the sample have a university degree, whereas in England and Wales this is only 40.4%. In 
total, 54.8% of the GLAD sample have a university degree compared to 27.2% of the English and Welsh 
population. Matching educational attainment data was not readily available for Northern Ireland and 
Scotland. 
 
 
 
 
Table 2. Descriptors of GLAD sample, July 2019 
    Percent* 
Sex 
  Male 20.3% 
  Female 79.7% 
Gender   
  Transgender 1.5% 
Sexuality 
  Heterosexual 73.4% 
  Homosexual 6.5% 
  Bisexual 15.5% 
  Asexual 1.3% 
  Self-define 3.1% 
Ethnicity 
  White 94.8% 
  Mixed 2.5% 
  Asian or Asian British 1.2% 
  Black or Black British 0.5% 
  Arab 0.1% 
  Other 0.9% 
Education (highest level achieved) 
  College or university degree 54.8% 
  A levels/AS levels or equivalent 22.7% 
  O levels/GCSEs or equivalent 14.8% 
  CSEs or equivalent 1.8% 
Employment 
  Employed 59.5% 
  Retired 5.7% 
  Unable to work because of sickness or disability 11.8% 
  Unemployed, looking after home/family, or doing voluntary work 8.9% 
  Full or part-time student 13.0% 
Relationship status 
  Single 27.8% 
  Relationship 32.2% 
  Married/civil partnership 30.3% 
  Divorced/separated 7.6% 
  Widowed 1.1% 
Smoking status 
  Current 17.5% 
  Former 31.9% 
  Never 50.6% 
Handedness 
  Right handed 87.2% 
  Left handed 11.1% 
  Ambidextrous 1.7% 
Received treatment** 
             Any treatment 96.1% 
             Psychological (talking) therapies 81.6% 
             Medication 89.7% 
*Where totals do not sum to 100%, the remaining % was due to incomplete data from those who declined to answer.  
**Treatment percentages were only calculated for participants who screened positively for MDD or GAD. Participants were 
asked to select all that applied in response to the question “Did you ever try or are currently trying the following for these 
problems?” Participants are considered to have received treatment if they indicated they tried medication prescribed for at 
least two weeks or tried psychotherapy or other talking therapy more than once.  
 
Figure 4. Distribution of sex and age in the GLAD sample compared to the UK population 
 
Comparison of age and sex characteristics between the GLAD sample and the general population of the UK as measured in the 2011 census 
(Office for National Statistics, National Records of Scotland, and Northern Ireland Statistics and Research Agency 2016). Proportions of males in 
each age group are displayed on the left side of the graph, with female proportions on the right. Percentages represent the proportion out of 
the respective sample as a whole (GLAD or UK). For example, 2.8% of the UK population is male aged 16-19, compared to 0.7% of the GLAD 
population. GLAD participants are represented in light (male) and dark (female) shades of blue, while the UK population is represented in light 
(male) and dark (female) shades of green.  
 
 
 
 
 
 
 
Figure 5. Proportion of individuals with university degrees within age groups in the GLAD sample 
compared to the English and Welsh population 
 Comparison of education level by age group between the GLAD sample and the general population of England and Wales as measured in the 
2011 census (Office for National Statistics, National Records of Scotland, and Northern Ireland Statistics and Research Agency 2016). Data for 
Northern Ireland and Scotland was not readily available.
 
Proportions of individuals without university degrees within each age group are 
displayed on the left side of the graph, with proportions of individuals with university degrees on the right. Percentages represent the 
proportion within each age group with or without a university degree. For example, 14% of the English population between the ages of 16-24 
have a university degree compared to 36% of the GLAD population. GLAD participants are represented in dark (no university degree) and light 
(university degree) shades of blue, while the English/Welsh population is represented in dark (no university degree) and light (university 
degree) shades of green.  
 
A high proportion of GLAD participants report the occurrence of at least one form of trauma or abuse 
throughout their lives. Child abuse was most commonly reported, with emotional abuse by parents or 
family being endorsed by  42.1% of the sample (in comparison to the estimated 9% of adults in England 
and Wales who experienced emotional abuse as a child (Office for National Statistics 2016)). Other 
forms of life stress are also frequently endorsed with 62.8% of the sample reporting at least one 
traumatic experience in their lives. Of note, few participants reported periods of inability to pay rent, 
reflecting low rates of poverty in the sample.  
 
 
 
 
 
 
 
 
 
Table 3. Proportion of the GLAD sample reporting previous child abuse/neglect, domestic abuse, or 
traumatic life events 
 Proportion of sample 
Child abuse/neglect
a 
  Any abuse or neglect 55.4% 
     Emotional abuse 42.1% 
     Physical abuse 20.2% 
     Sexual abuse 20.1% 
     Emotional neglect 14.8% 
     Physical neglect 4.2% 
Domestic abuse
b 
  Any abuse 30.6% 
     Emotional abuse 37.0% 
     Physical abuse 19.0% 
     Sexual abuse 22.6% 
Stressful life event 
  Any stressful/traumatic life eventd 62.8% 
     Sexual assaultc 44.7% 
     Attacked, mobbed, or robbedc 26.7% 
     Life-threatening accidentc 13.3% 
     Witnessed sudden/violent deathc 15.4% 
     Life-threatening illnessc 8.8% 
     War zonec 2.1% 
     Inability to pay rent 1.6% 
a
Childhood abuse was assessed by the Childhood Trauma Survey (CTS) (Glaesmer et al. 2013) which includes 5 items on a Likert scale, each 
relating to the frequency of a distinct type of abuse (emotional, physical, sexual) or neglect (emotional, physical). Percentages reflect the 
proportion of the sample scoring above the defined cut-off point for clinical utility on each item out of the total. 
b
Domestic abuse and inability 
to pay rent was assessed by a separate adult trauma scale without pre-defined cut-offs, therefore cut-off points were devised by the study 
team based on the CTS scoring.  
a,b
Any abuse or stressful/traumatic life event was defined as individuals who scored above the cut-off on at 
least one item on the respective scale. 
c
The remaining stressful life events were assessed by combining the sum total of participants indicating 
“Yes, in the past 12 months” or “Yes, but not in the past 12 months” for each item. 
d
Any stressful/traumatic life event was defined as individuals 
who scored above the cut-off point for inability to pay rent or indicated they had experienced one of the stressful/traumatic life events either in 
the past 12 months or in their lifetime. 
 
Psychopathology 
As shown in Figure 6, the majority of participants reached diagnostic criteria for major depressive 
disorder, followed by panic disorder and generalised anxiety disorder. The majority of participants with 
depression reported recurrent episodes across the lifespan. A figure demonstrating self-reported 
clinician-provided diagnoses of mental health disorders (as opposed to questionnaire-assessed) in the 
GLAD sample can be found in supplementary materials (SM 3). Of note, self-reported clinician-provided 
diagnoses of GAD (77.2%) are twice as high as cases assessed by the questionnaire. The sample also has 
high rates of comorbidity, with 67.0% of screened MDD cases also screening positively for at least one of 
the anxiety disorders (GAD, specific phobia, social phobia, panic disorder, or agoraphobia), and 95.1% of 
screened GAD cases also screening positively for MDD.  
 
 
 
Figure 6. Lifetime prevalence of probable psychiatric disorders in the GLAD sample. 
 Percentages refer to the proportion of participants who meet cut-off criteria on lifetime measures for the specified disorder as defined by the 
DSM-5 (American Psychiatric Association 2013) out of the total. Possible mania was assessed by the Mood Disorder Questionnaire (MDQ) 
(Hirschfeld 2002).  
 
Retrospective reports of age of onset indicate a young average onset for the lifetime measures of MDD, 
GAD, specific phobia, social phobia, panic disorder, and agoraphobia (Table 4). Average age of onset 
across the anxiety disorders was ~15. Age of onset for GAD was added to the questionnaire in May 
2019, therefore the descriptives below are based on responses from a subset of participants recruited 
after that date. 
 
Table 4. Age of onset in GLAD sample for major depressive disorder, specific phobias, social phobia, 
panic disorder, and agoraphobia 
 Median Mean SD 
Major depressive disorder 16 18.61 8.98 
Generalised anxiety disorder 16 19.37 11.87 
Specific phobia 10 11.32 8.40 
Social phobia 12 13.79 8.64 
Panic disorder 16 18.80 10.21 
Agoraphobia 15 16.90 10.10 
 
 
Measures of current symptoms of psychopathology included in the questionnaire demonstrate high 
rates of current clinical presentation of MDD and GAD, with high levels of functional impairment (Table 
5).  
 
Table 5. Current symptoms of psychopathology and impairment in the GLAD sample. 
 Mean Range SD Proportion Clinical Severity 
Major depressive disordera 11.00 0 - 27 6.92 Clinical (total) 83.7% 
         Mild (5 - 9) 24.7% 
         Moderate (10 - 14) 23.7% 
         Moderately severe (15 - 19) 18.7% 
         Severe (20+) 16.7% 
Generalised anxiety disorderb 9.43 0 - 21 6.02 Clinical (total) 75.5% 
     
Mild (5 - 9) 30.7% 
     
Moderate (10 - 14) 21.1% 
     
Severe (15+) 23.9% 
Post-traumatic stress disorderc 15.87 0-30 6.29 Clinical (14+) 60.2% 
Personality disorderd 8.30 0 - 25 3.65 Clinical (total) 55.0% 
     
Mild (8 - 9) 21.9% 
     
Moderate (10+) 33.1% 
Alcohol usee 7.06 0 - 40 6.48 At-risk (total) 38.7% 
         Increasing risk (8 - 15) 27.0% 
         Higher risk (16 - 19) 5.4% 
         Possible dependence (20+) 6.4% 
Functional Impairmentf 16.99 0-40 9.07 Clinical (total) 77.8% 
     
Significant impairment (10 - 20) 43.5% 
     
Severe impairment (21+) 34.4% 
Percentages refer to the proportion of participants out of the total sample who meet cut-off criteria on current measures for the specified disorder: 
a 
Criteria 
met for major depressive disorder on PHQ-9 (Kroenke, Spitzer, and Williams 2001) 
b 
Criteria met for generalised anxiety disorder on GAD-7 (Spitzer et al. 2006) 
c
 Criteria met for PTSD on PCL-6 (Lang et al. 2012) in the past month 
d
 Criteria met for a personality disorder on SASPD (Olajide et al. 2018) 
e
 Criteria met for at-
risk alcohol dependence on AUDIT (Saunders et al. 1993) in the past year 
f
 Criteria met for functional impairment on WSAS (Mundt et al. 2002)  
 
Media Campaign 
In order to assess the success of the media campaign, participants were asked to report how they found 
out about the GLAD Study at the end of the sign-up questionnaire. Results of the campaign were 
assessed 3 months after the initial launch in England. Participants who completed the questionnaire 
reported that the three most common ways of hearing about the study were through Facebook, print 
newspaper, and Twitter (SM 4). 
 
The effectiveness of each recruitment strategy varied by age (see Figure 7). Of participants aged 16-29, 
the majority learned about the study through social media (Facebook, Twitter, Instagram, search 
engine), with only 12% receiving study information through traditional media (TV, radio, print 
newspaper, online tabloid). Participants aged 30-49 also primarily learned about the study through 
social media, but 22% within that range learned about the study through traditional media. Social media 
was less effective in reaching individuals aged 50+, with traditional media being the primary means of 
recruitment above that age. 
 
 
 
 
Figure 7. Media campaign drivers to complete questionnaires, by age group 
 Data is based on responses from 12,714 participants recruited in England between September - December 2019 to assess the success of the 
launch campaign. Participants were prompted to select all relevant responses to the question “How did you hear about the GLAD Study?” Social 
media refers to Facebook, Twitter, Instagram, bloggers, and search engines. Traditional media refers to radio, TV, newspaper, and online 
tabloids. All remaining responses are included in the Other category. 
 
Discussion 
The GLAD Study represents a large and comprehensive study of anxiety and depression and a valuable 
resource for future research. By achieving our goal of recruiting 40,000 participants with a lifetime 
occurrence of one of these disorders into the NIHR Mental Health BioResource, the study will collect 
detailed, homogenous phenotype and genotype data, thereby increasing power for genetic analyses. 
Importantly, the recontactable nature of GLAD means that researchers will be able to conduct new 
studies integrating psychological and genetic data. 
 
Why integrate genetic data? GLAD provides researchers with a way of investigating polygenic and 
environmental effects in studies with participants. As such, the study is not merely a way to increase 
GWAS sample size, but also a way to increase the potential utility of genomics within psychological 
studies of all kinds. Previous efforts in depression and anxiety genetics have been hampered by the 
unreliable methodology of candidate gene studies (Border et al. 2019). However, Border also concluded 
that modern and successful genome-wide studies of depression, rigorously testing millions of genetic 
variants in large samples (e.g. CONVERGE consortium 2015; Wray et al. 2018), provide reliable evidence. 
The implications that these highly complex, but highly replicable, polygenic effects have for the field 
need to be investigated (Hyman 2018). GLAD exists to enable recruitment of participants into studies 
not only on the basis of their self-reported information and/or clinical records, but also on the basis of 
the increasingly well powered method of polygenic risk scoring. This approach combines risk alleles 
across the genome into a single quantitative measure for any one individual (Belsky and Harden 2019). 
For instance, a clinical trial could be undertaken with selection of participants based on past medical 
history and/or polygenic scores for a relevant trait. 
 
External researchers will be able to apply for access to anonymised data and will have the opportunity to 
recontact participants for additional data collection. This offers the prospect of a wide range of future 
recall studies, including clinical trials, observational studies, neuroimaging, and experimental medicine. 
Recruitment for recall studies could also be targeted to participants with phenotypes or genotypes of 
interest by utilising GLAD data to screen for specific eligibility criteria, thereby simplifying and expediting 
the recruitment process for future studies. Furthermore, measures were in part selected to match other 
cohorts and facilitate meta-analysis with samples such as the UK Biobank, Generation Scotland, and the 
Australian Genetics of Depression Study, although demographic differences between the samples would 
need to be taken into account (e.g. age differences between GLAD and UK Biobank participants). We 
propose that the GLAD data could be useful for stratifying cases into distinct phenotypes of depression 
and anxiety to reduce heterogeneity, a strategy which has been shown to increase the power of genetic 
analyses to detect significant effects (CONVERGE consortium 2015; Power et al. 2017; Verduijn et al. 
2017). 
  
Initial descriptive analyses reveal that the current GLAD sample does not reflect the demographics of the 
general population of the UK. The limited ethnic diversity within the sample is not representative, with 
95% of participants being white compared to 87% of the population (Office for National Statistics, 
National Records of Scotland, and Northern Ireland Statistics and Research Agency 2016). Similarly, 
although common mental disorders are more than twice as common in young women compared to 
young men, and 1.5 times more common in women overall (NHS Digital 2016), the GLAD sample 
remains disproportionately female. Finally, roughly double the proportion of the study sample report 
having a university degree compared to the English and Welsh population.  
 
The GLAD sample as a whole also shows severe psychopathology. Our lifetime questionnaire diagnostic 
algorithm indicated that the majority of the sample have recurrent depression, and 20.9% report 
possible mania/hypomania. Over half the sample screen positively for a lifetime anxiety disorder, with 
panic disorder being the most common. Participants also show substantial comorbidity, in particular for 
GAD cases reporting a concurrent diagnosis of MDD. Our results show significantly higher comorbidity 
rates for GAD cases compared to a previous epidemiological study whereby 62.4% of GAD cases had a 
lifetime occurrence of MDD (Judd et al. 1998). However, this is likely further indication of the sample’s 
severity, reflecting previous reports of higher rates of comorbid anxiety in patients with recurrent 
lifetime depression (Moffitt et al. 2007; Boland, Keller, Gotlib, and Hammen 2002). In terms of current 
symptoms, GLAD participants report moderate symptoms of depression, mild to moderate symptoms of 
anxiety, and significant functional impairment, indicating poor work and social adjustment. Finally, it 
was interesting to note that 55.0% of participants screened positive for mild-moderate personality 
disorder.  
 
Severity levels are also demonstrated by the 96.1% of GLAD participants who report receiving treatment 
for depression or anxiety, although the study is open to individuals regardless of treatment receipt. In 
Western countries, it is estimated that between one-thirds and one-half of patients with depression or 
anxiety disorders do not receive a diagnosis and/or treatment (Kessler et al. 2002), a group not 
represented in our sample. However, even in those patients receiving treatment, recent research 
suggests that only 20% get minimally adequate treatment (Thornicroft et al. 2017), meaning that follow-
up research on treatment efficacy in the GLAD sample would be highly valuable.  
 
An unanticipated benefit of the campaign was the interest it generated from UK NHS sites around the 
country. Over 100 NHS sites, including Trusts and GP practices, contacted the study team with interest in 
supporting recruitment, and many had learned about the study from the media campaign. The study 
was also adopted onto the NIHR Clinical Research Network (CRN) Portfolio which provides support and 
funding for NHS organisations that are involved in research. The combined approach of both general and 
clinical recruitment reaches a wider demographic of participants than either strategy alone. Patients 
recruited through clinics can also be assisted in signing up by a local clinician or research team to 
provide support throughout the process if needed. 
 
In addition to collecting a large amount of data, the GLAD study represents a template for future online 
studies. The media campaign proved highly effective in recruiting a large number of participants in a 
short amount of time and demonstrates the success of such a broad outreach approach.  Caution must 
be taken when interpreting the success of the different media campaign strategies, given the prolonged 
use of social media promotions in comparison to traditional media outlets; nonetheless social media 
was the most effective strategy for recruiting individuals under 50. Recruiting younger participants not 
only reflects the young average age of onset of anxiety and depression, approximately 11 (Bandelow 
and Michaelis 2015) and 24 (Christie et al. 1988; Kessler et al. 2003) respectively, but also helps to 
facilitate long-term follow up and recontact. 
 
Limitations 
As previously mentioned, the current demographics of study participants who completed the 
questionnaire are not representative of the population of the UK. This suggests a selection bias 
comparable to what has been observed in similar studies such as the UK BioBank (Fry et al. 2017; Adams 
et al. 2019). Results from analyses of the current GLAD sample therefore may not be generalisable to 
the whole population. Smaller studies could overcome these biases by selectively over-sampling males 
and individuals at the lower end of educational attainment to be more representative of the population.  
 
However, efforts are being taken to recruit a wider demographic of participants into the study. 
Specifically, we will develop a targeted social media campaign to reach young men and collaborate with 
young male influencers to appeal to that audience. We will additionally prepare a future media 
campaign that focuses on depression and anxiety separately, with wording specific to each disorder, to 
attempt to reduce the high comorbidity rates in the sample. Furthermore, we are collaborating with 
local branches of the charity Mind. These are typically placed within the community and provide a range 
of mental health support services. Branches will be displaying posters and leaflets on site, posting on 
social media, and answering questions or providing assistance to potential participants interested in 
signing up. Recruitment through NHS services and the availability of local research teams within those 
sites will also help reach the general population and recruit individuals with a wider range of educational 
attainment.   
 
Of particular importance, we are working with Black, Asian, and minority ethnic charities and influencers 
to conduct additional user testing to understand the barriers to participating for non-white individuals 
and increase outreach to diverse communities. Previous genetic studies have involved primarily 
individuals of white European ancestry (Haga 2010), and findings from these studies may not apply to 
individuals of non-white descent. By actively recruiting a diverse sample, our objective is to additionally 
facilitate research on typically underrepresented groups. 
 
Another challenge of the study design is the drop-out rates following recruitment. At each stage of the 
sign-up process, a substantial number of participants did not complete the next step despite multiple 
reminders. Unfortunately, we are unable to assess the demographics of participants who do not 
complete the sign-up questionnaire, but it is possible that the drop-outs are non-random and represent 
a certain phenotype, such as individuals with more severe symptoms or lower health literacy.  
 
Conclusion 
The GLAD study offers a recontactable resource of participants with a lifetime occurrence of depression 
and anxiety disorders to facilitate future health research. The online study design and media 
recruitment strategy were effective in recruiting a large number of individuals with these disorders into 
the NIHR Mental Health BioResource. Recruitment is ongoing with the goal of completing recruitment of 
40,000 individuals, making this the largest single study of depression and anxiety. We hope that this 
paper will not only demonstrate the effectiveness of the study methodology but will also raise 
awareness of the availability of this cohort to researchers in the field and promote future collaboration. 
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